Cargando…

Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP‐NETs: A Review of Key Issues

Octreotide acetate (octreotide) is the most prescribed and most studied somatostatin congener, or analog, for gastroenteropancreatic neuroendocrine tumors (GEP‐NETs) and carcinoid syndrome, the latter of which may be characterized by debilitating diarrhea and flushing. Approved in the U.S. more than...

Descripción completa

Detalles Bibliográficos
Autores principales:	Anthony, Lowell B., O'Dorisio, Thomas M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Gastrointestinal Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265352/ https://www.ncbi.nlm.nih.gov/pubmed/34097784 http://dx.doi.org/10.1002/onco.13847

Ejemplares similares

Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up
por: Duan, Heying, et al.
Publicado: (2022)

Growing vascular endothelial cells express somatostatin subtype 2 receptors
por: Watson, J C, et al.
Publicado: (2001)

The current status of somatostatin receptors in malignant melanoma.
por: Fletcher, W. S., et al.
Publicado: (1997)

PET and PET/CT with (68)Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors
por: Sollini, Martina, et al.
Publicado: (2014)

Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
por: Fujii, Hironori, et al.
Publicado: (2019)

Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study
por: Zhao, Lulu, et al.
Publicado: (2023)

Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy
por: Cheng, Zhi, et al.
Publicado: (2018)

Relationship between somatostatin receptor expressing tumour volume and health‐related quality of life in patients with metastatic GEP‐NET
por: Ohlsson, Håkan, et al.
Publicado: (2022)

Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma
por: Canton, Clémence, et al.
Publicado: (2022)

Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status
por: Wood, Anthony C, et al.
Publicado: (2022)

Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance)
por: Singh, Preet Paul, et al.
Publicado: (2016)

Clinical Practice Observation of Trastuzumab in Patients with Human Epidermal Growth Receptor 2‐Positive Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
por: Al‐Batran, Salah‐Eddin, et al.
Publicado: (2020)

Comparison of Four Clinical Prognostic Scores in Patients with Advanced Gastric and Esophageal Cancer
por: Ma, Lucy X, et al.
Publicado: (2022)

KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas
por: Diehl, Adam C, et al.
Publicado: (2022)

Long-term analysis of 2 prospective studies that incorporate mitomycin C into an adjuvant chemoradiation regimen for pancreatic and periampullary cancers
por: Schunke, Kathryn J., et al.
Publicado: (2017)

Trends in intensity modulated radiation therapy use for locally advanced rectal cancer at National Comprehensive Cancer Network centers
por: Reyngold, Marsha, et al.
Publicado: (2017)

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study
por: Moriwaki, Toshikazu, et al.
Publicado: (2017)

Feasibility of definitive chemoradiation therapy with nedaplatin and 5-fluorouracil in elderly patients with esophageal squamous cell carcinoma: A retrospective study
por: Watanabe, Akinori, et al.
Publicado: (2018)

Initial experience with intensity modulated proton therapy for intact, clinically localized pancreas cancer: Clinical implementation, dosimetric analysis, acute treatment-related adverse events, and patient-reported outcomes
por: Jethwa, Krishan R., et al.
Publicado: (2018)

The role of bone marrow and spleen irradiation in the development of acute hematologic toxicity during chemoradiation for esophageal cancer
por: Chin, Alexander L., et al.
Publicado: (2018)

A Comparison of Grade 4 Lymphopenia With Proton Versus Photon Radiation Therapy for Esophageal Cancer
por: Routman, David M., et al.
Publicado: (2019)

Stereotactic Ablative Radiation Therapy for Unresectable Colorectal Oligometastases
por: Sutera, Philip, et al.
Publicado: (2018)

Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report
por: Wolfe, Adam R., et al.
Publicado: (2018)

High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive Chemoradiotherapy
por: Mitra, Devarati, et al.
Publicado: (2019)

Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy
por: Zhou, Xi‐Lei, et al.
Publicado: (2019)

Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases
por: Gao, Robert W., et al.
Publicado: (2019)

Initial Results of a Prospective Study of Adjuvant Pancreatic Stereotactic Body Radiation Therapy for Close or Positive Margins
por: Bernard, Mark E., et al.
Publicado: (2018)

Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers
por: David, John M., et al.
Publicado: (2018)

Initial Report of Second‐Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi‐Institutional Retrospective Analysis
por: Klempner, Samuel J., et al.
Publicado: (2018)

Pancreas Cancer‐Associated Weight Loss
por: Hendifar, Andrew E., et al.
Publicado: (2018)

Radiation Therapy Dose Escalation to Clinically Involved Pelvic Sidewall Lymph Nodes in Locally Advanced Rectal Cancer
por: Hartvigson, Pehr E., et al.
Publicado: (2019)

Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation
por: Jensen, Garrett, et al.
Publicado: (2018)

Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States
por: Abdel-Rahman, Omar, et al.
Publicado: (2018)

A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803
por: Niedzwiecki, Donna, et al.
Publicado: (2016)

Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors
por: Ter‐Minassian, Monica, et al.
Publicado: (2017)

HASPIN kinase inhibitor CHR-6494 suppresses intestinal polyp development, cachexia, and hypogonadism in Apc(min/+) mice
por: Tanaka, Hiromitsu, et al.
Publicado: (2019)

Safety and Feasibility of Additional Tumor Debulking to First‐Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer
por: Gootjes, Elske C., et al.
Publicado: (2020)

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2020)

How Much Was the Elective Lymph Node Region Covered in Involved-Field Radiation Therapy for Locally Advanced Pancreatic Cancer? Evaluation of Overlap Between Gross Target Volume and Celiac Artery–Superior Mesenteric Artery Lymph Node Regions
por: Umezawa, Rei, et al.
Publicado: (2019)

IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer
por: Moningi, Shalini, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1s4u5k40c1vqd0v3u059uer7hm